Metabolic syndrome, diabetes, and hyperuricemia

Current Opinion in Rheumatology

Volumn 25, Issue 2, 2013, Pages 210-216

  Li, Changgui ^a   Hsieh, Ming Chia ^b   Chang, Shun Jen ^c  

^a QINGDAO UNIVERSITY   (China)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

Author keywords

hyperuricemia; insulin resistance; metabolic syndrome; type 2 diabetes

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRIACYLGLYCEROL; URATE; URIC ACID;

ADIPOSE TISSUE; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DENDRITIC CELL; DIABETES MELLITUS; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE MIGRATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ADULT; ALCOHOL DRINKING; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERURICEMIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS;

EID: 84873351689     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835d951e     Document Type: Review

References (88)

1. Singh JA, Reddy SG, Kundukulam J. Riskfactors for gout and prevention: a systematic reviewof the literature. Curr Opin Rheumatol 2011;23:192-202.
2. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005; 20:1029-1033.
3. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48:1037-1042.
4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012; 125:679-687.
5. Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes:a 15-yearfollow-upstudy. Am J Epidemiol 2012; 176:108-116.
6. Yoo HG, Lee SI, Chae HJ, et al. Prevalenceof insulin resistanceand metabolic syndrome in patients with gouty arthritis. Rheumatol Int 2011; 31:485-491.
7. Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010; 9:17.
8. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23:171-175.
9. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf) 2011; 203:279-286.
10. Chen SJ, Yen CH, Huang YC, et al. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. Plos One 2012; 7:e45693.
11. Jialal I, Devaraj S, Adams-Huet B, et al. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab 2012; 97:E1844-E1850.
12. Hulsmans M, Geeraert B, DeKeyzer D, et al. Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome. Plos One 2012; 7:e30414.
13. Lai HM, Chen CJ, Su BY, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic riskfactors and higher incidences. Rheumatol-ogy (Oxford) 2012; 51:715-720.
14. Grundy SM. Metabolic syndrome: a multiplexcardiovascular riskfactor. J Clin Endocrinol Metab 2007; 92:399-404.
15. Wassink AM, van der Graaf Y, van Haeften TW, et al. Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases: a cohort study. Diabet Med 2011; 28:932-940.
16. Lee WY, Park JS, Noh SY, et al. Prevalence of the metabolicsyndromeamong 40 698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004; 65:143-149.
17. Uaratanawong S, Suraamornkul S, Angkeaw S, Uaratanawong R. Prevalence of hyperuricemiain Bangkokpopulation. Clin Rheumatol 2011; 30:887-893.
18. Lim JH, Kim YK, Kim YS, et al. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in korean. Korean Circ J 2010; 40:314-320.
19. Lin SD, Tsai DH, Hsu SR. Association between serum uricacid level and com-ponents of the metabolic syndrome. J Chin Med Assoc 2006; 69:512-516.
20. Barbosa MCC, Brandão AA, Pozzan R, et al. Association between uric acid and cardiovascular risk variables in a nonhospitalized population. Arquivos Brasileiros De Cardiologia 2011; 96:212-218.
21. Lee JM, Kim HC, Cho HM, et al. Association betweenserum uricacid level and metabolic syndrome. J Prev Med Public Health 2012; 45:181-187.
22. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individualswith hyperuricemia. Am J Med 2007; 120:442-447.
23. Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2011; 10:72.
24. Rodrigues SL, Baldo MP, Capingana P, et al. Gender distribution of serum uric acid and cardiovascular riskfactors: population based study. Arquivos Brasileiros De Cardiologia 2012; 98:13-21.
25. Meshkani R, Zargari M, Larijani B. The relationship between uric acid and metabolic syndrome in normal glucose tolerance and normal fasting glucose subjects. Acta Diabetologica 2011; 48:79-88.
26. Liu P-W, Chang T-Y, Chen J-D. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism 2010; 59:802-807.
27. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. Jama 1991; 266:3008-3011.
28. Del Prato S, Leonetti F, Simonson DC, et al. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensi-tivity in man. Diabetologia 1994; 37:1025-1035.
29. Bertacca A, Ciccarone A, Cecchetti P, et al. Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. Metabolism 2005; 54:1687-1693.
30. Mikhail N. The metabolic syndrome: insulin resistance. Curr Hypertens Rep 2009; 11:156-158.
31. Ferrannini E, Natali A, Capaldo B, et al. Insulin resistance, hyperinsulinemia, and blood pressure: role ofageand obesity. European Groupforthe Study of Insulin Resistance (EGIR). Hypertension 1997; 30:1144-1149.
32. Ferrannini E. Is insulin resistance the cause of the metabolic syndrome? Ann Med 2006; 38:42-51.
33. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41:369-379.
34. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus-the urate redox shuttle. Nutr Metab (Lond) 2004; 1:10.
35. Marotta T, Russo BF, Ferrara LA. Triglyceride-to-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients. Obesity (Silver Spring) 2010; 18:1608-1613.
36. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802-809.
37. Karelis AD, Pasternyk SM, Messier L, et al. Relationship between insulin sensitivity and the triglyceride-HDL-C ratio in overweight and obese post-menopausal women: a MONET study. Appl Physiol Nutr Metab 2007; 32:1089-1096.
38. Giannini C, Santoro N, Caprio S, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care 2011; 34:1869-1874.
39. Yamashita M, Tamasawa N, Matsuki K, et al. Insulin suppresses HDL-mediated cholesterol efflux from macrophages through inhibition of neutral cholesteryl ester hydrolase and ATP-binding cassette transporter G1 expres-sions. J Atheroscler Thromb 2010; 17:1183-1189.
40. Gastaldelli A, Sironi AM, Ciociaro D, et al. Visceralfatand betacellfunction in nondiabetic humans. Diabetologia 2005; 48:2090-2096.
41. Hotamisligil MF, Gregor GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29:415-445.
42. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72:219-246.
43. Kitade H, Sawamoto K, Nagashimada M, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012; 61:1680-1690.
44. McCurdy CE, Schenk S, Holliday MJ, et al. Attenuated Pik3r1 expression prevents insulin resistance and adipose tissue macrophage accumulation in diet-induced obese mice. Diabetes 2012; 61:2495-2505.
45. Stefanovic-Racic M, Yang X, Turner MS, et al. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver. Diabetes 2012; 61:2330-2339.
46. Michaud A, Drolet R, Noel S, et al. Visceral fat accumulation is an indicator of adiposetissue macrophage infiltration inwomen. Metabolism2012; 61:689-698.
47. Engelman JA, Berg AH, Lewis RY, et al. Tumornecrosisfactoralpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14:1557-1569.
48. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272:971-976.
49. Stagakis I, Bertsias G, Karvounaris S, et al. Antitumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012; 14:R141.
50. Yamato M, Shiba T, Ide T, et al. High-fat diet-induced obesity and insulin resistance were ameliorated via enhanced fecal bile acid excretion in tumor necrosis factor-alpha receptor knockout mice. Mol Cell Biochem 2012; 359:161-167.
51. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004; 140:211-219.
52. Koppes LL, Dekker JM, Hendriks HF, et al. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observa-tional studies. Diabetes Care 2005; 28:719-725.
53. Kawamoto R, Kohara K, Tabara Y, et al. Alcohol consumption is associated with decreased insulin resistance independent of body mass index in Japa-nese community-dwelling men. Tohoku J Exp Med 2009; 218:331-337.
54. Longato L, Ripp K, Setshedi M, et al. Insulin resistance, ceramide accumula-tion, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev 2012; 2012:479348.
55. de la Monte SM, Yeon JE, Tong M, et al. Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol 2008; 23:e477-e486.
56. Ishizaka N, Ishizaka Y, Toda E, et al. Association between gamma-glutamyl-transferase levels and insulin resistance according to alcohol consumption and numberofcigarettessmoked. J Atheroscler Thromb 2010; 17:476-485.
57. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994; 78:25-29.
58. Robles-Cervantes JA, Ramos-Zavala MG, Gonzalez-Ortiz M, et al. Relation-ship between serum concentration of uric acid and insulin secretion among adults with type 2 diabetes mellitus. Int J Endocrinol 2011; 2011:107904.
59. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69:928-933.
60. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55:1293-1301.
61. Carnethon MR, Fortmann SP, Palaniappan L, et al. Riskfactors for progres-sion to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158:1058-1067.
62. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011; 60:1258-1269.
63. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011; 23:156-160.
64. Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995; 268:E1-E5.
65. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9:746-752.
66. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30:928-931.
67. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 2002; 15:697-701.
68. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21:457-468.
69. Tambascia MA, Geloneze B, Repetto EM, et al. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003; 5:338-344.
70. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31:15-22.
71. Ter Maaten JC, Voorburg A, Heine RJ, et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997; 92:51-58.
72. Mandel LJ. Primary active sodium transport, oxygen consumption, and ATP: coupling and regulation. Kidney Int 1986; 29:3-9.
73. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290:F625-F631.
74. Cook S, Hugli O, Egli M, et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 2003; 133:360-363.
75. Baldus S, Koster R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 2005; 39:1184-1190.
76. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
77. Roy D, Perreault M, Marette A. Insulin stimulation ofglucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol 1998; 274:E692-E699.
78. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18:523-530.
79. Pan WH, Flegal KM, Chang HY, et al. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr 2004; 79: 31-39.
80. Sone H, Mizuno S, Ohashi Y, Yamada N. Type 2 diabetes prevalence in Asian subjects. Diabetes Care 2004; 27:1251-1252.
81. Jiang Y, Chen Y, Mao Y, Group COW. The contribution of excess weight to prevalent diabetes in Canadian adults. Public Health 2008; 122:271-276.
82. Chien KL, Chen MF, Hsu HC, et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 2008; 54:310-316.
83. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31:361-362.
84. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47:1567-1570.
85. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3:706-713.
86. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19:1209-1215.
87. Tuomilehto J, Zimmet P, Wolf E, et al. Plasmauricacid level and itsassociation with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127:321-336.
88. Herman JB, Medalie JH, Goldbourt U. Diabetes, prediabetes and uricaemia. Diabetologia 1976; 12:47-52.